Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Fish and Richardson
Baxter
Argus Health
Moodys
Express Scripts
Colorcon
Dow

Generated: December 18, 2018

DrugPatentWatch Database Preview

Par Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM, and what generic alternatives to PAR PHARM drugs are available?

PAR PHARM has two hundred and fifteen approved drugs.

There is one US patent protecting PAR PHARM drugs. There are fourteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and sixteen supplementary protection certificates in twelve countries.

Summary for Par Pharm

Drugs and US Patents for Par Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm HYDROXYZINE PAMOATE hydroxyzine pamoate CAPSULE;ORAL 087657-001 Jun 11, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Par Pharm Inc MIDODRINE HYDROCHLORIDE midodrine hydrochloride TABLET;ORAL 207169-003 Oct 29, 2018 AB RX No No ➤ Sign Up ➤ Sign Up
Par Pharm RISPERIDONE risperidone TABLET, ORALLY DISINTEGRATING;ORAL 077494-003 Oct 26, 2009 AB RX No No ➤ Sign Up ➤ Sign Up
Par Pharm HYDRA-ZIDE hydralazine hydrochloride; hydrochlorothiazide CAPSULE;ORAL 088946-001 Oct 21, 1985 RX No Yes ➤ Sign Up ➤ Sign Up
Par Pharm AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 088698-001 Sep 25, 1984 DISCN No No ➤ Sign Up ➤ Sign Up
Par Pharm ISOSORBIDE DINITRATE isosorbide dinitrate TABLET;ORAL 086925-001 Mar 12, 1987 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Par Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 5,612,367 ➤ Sign Up
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-007 Jun 13, 1995 4,215,104 ➤ Sign Up
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-004 Jun 13, 1995 4,258,027 ➤ Sign Up
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 5,482,963 ➤ Sign Up
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 6,143,775 ➤ Sign Up
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-003 Approved Prior to Jan 1, 1982 5,238,924 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PAR PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 500 mcg/spray ➤ Subscribe 2017-04-28
➤ Subscribe Tablets 10 mg and 20 mg ➤ Subscribe 2008-02-29

Supplementary Protection Certificates for Par Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
07C/043 Belgium ➤ Sign Up PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
C/GB97/088 United Kingdom ➤ Sign Up PRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827
C0005 Belgium ➤ Sign Up PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
C0041 France ➤ Sign Up PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C/GB98/033 United Kingdom ➤ Sign Up PRODUCT NAME: ZAFIRLUKAST AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: IE PA 51/67/1 19960103; UK 12619/0108 19980605
C/GB11/015 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Harvard Business School
Argus Health
Baxter
McKinsey
Merck
US Army
QuintilesIMS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.